# OnCo record create-x (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/create-x/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "create-x" ;
  schema:name "CREATE-X"@en ;
  schema:alternateName "JBCRG-04"@en, "CREATE-X/JBCRG-04"@en, "UMIN000000843"@en ;
  schema:description "CREATE-X showed that giving the tablet chemotherapy capecitabine for six months after surgery, to women whose breast cancer had not fully disappeared with pre-operative chemotherapy, cut deaths; the gain was largest in triple-negative disease, where five-year survival rose from 70 to 79 percent."@en ;
  schema:url <https://onco.cc/trials/create-x/> ;
  schema:dateModified "2026-09-24"^^xsd:date ;
  schema:citation <https://doi.org/10.1056/NEJMoa1612645>, <https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000001004> ;
  onco:status "positive" ;
  onco:tag "registry:umin" ;
  onco:phase "3" ;
  onco:cancers <https://onco.cc/cancers/tnbc/>, <https://onco.cc/cancers/tnbc-early/>, <https://onco.cc/cancers/breast-hr-positive/> ;
  onco:technologies <https://onco.cc/technologies/cytotoxic-chemotherapy/> ;
  onco:drugs <https://onco.cc/drugs/capecitabine/> ;
  onco:terms <https://onco.cc/terms/rcb/>, <https://onco.cc/terms/efs/>, <https://onco.cc/terms/hand-foot-syndrome/>, <https://onco.cc/terms/tnbc-residual-disease-decision/> ;
  onco:trials <https://onco.cc/trials/sysucc-001/>, <https://onco.cc/trials/geicam-ciboma/>, <https://onco.cc/trials/ea1131/>, <https://onco.cc/trials/ascent-05/>, <https://onco.cc/trials/tropion-breast03/> .